Insider Trading Alert - SPLK, PODD And STKL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 8, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $33,225,000.00.

Highlighted Stocks Traded by Insiders:

Splunk (SPLK) - FREE Research Report

Smith Graham, who is Director at Splunk, sold 5,000 shares at $66.21 on June 8, 2015. Following this transaction, the Director owned 74,126 shares meaning that the stake was reduced by 6.32% with the 5,000-share transaction.

The shares most recently traded at $66.61, up $0.40, or 0.6% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 50,000
  • 12-Week # shares sold: 164,418
  • 24-Week # shares sold: 293,044

The average volume for Splunk has been 2.1 million shares per day over the past 30 days. Splunk has a market cap of $8.6 billion and is part of the technology sector and computer software & services industry. Shares are up 15.27% year-to-date as of the close of trading on Monday.

Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company's products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users. Currently, there are 21 analysts who rate Splunk a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Insulet (PODD) - FREE Research Report

Sullivan Patrick J, who is President & CEO at Insulet, bought 10,000 shares at $29.39 on June 8, 2015. Following this transaction, the President & CEO owned 83,650 shares meaning that the stake was boosted by 13.58% with the 10,000-share transaction.

The shares most recently traded at $29.81, up $0.42, or 1.42% since the insider transaction. Historical insider transactions for Insulet go as follows:

  • 4-Week # shares bought: 23,500
  • 4-Week # shares sold: 2,483
  • 12-Week # shares bought: 28,169
  • 12-Week # shares sold: 8,862
  • 24-Week # shares bought: 38,169
  • 24-Week # shares sold: 19,362

The average volume for Insulet has been 799,800 shares per day over the past 30 days. Insulet has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are down 34.85% year-to-date as of the close of trading on Monday.

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. Currently, there are 7 analysts who rate Insulet a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PODD - FREE

TheStreet Quant Ratings rates Insulet as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full Insulet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SunOpta (STKL) - FREE Research Report

Kendall Jeremy, who is Director at SunOpta, sold 50,000 shares at $12.72 on June 8, 2015. Following this transaction, the Director owned 424,164 shares meaning that the stake was reduced by 10.54% with the 50,000-share transaction.

The shares most recently traded at $10.54, down $2.18, or 20.7% since the insider transaction. Historical insider transactions for SunOpta go as follows:

  • 4-Week # shares bought: 2,385
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 21,615
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 23,796
  • 24-Week # shares sold: 100,000

The average volume for SunOpta has been 294,700 shares per day over the past 30 days. SunOpta has a market cap of $693.4 million and is part of the consumer goods sector and food & beverage industry. Shares are down 10.72% year-to-date as of the close of trading on Monday.

SunOpta Inc. sources, processes, packages, and markets natural, organic, and specialty food products in the United States, Canada, Europe, China, and Ethiopia. The company has a P/E ratio of 68.2. Currently, there are 3 analysts who rate SunOpta a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STKL - FREE

TheStreet Quant Ratings rates SunOpta as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full SunOpta Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing